A Case of Malignant Lymphomas that Healed Completely After Oral Administrations of 4-Hydroxybenzaldehyde

Volume 1 - Issue 5

Kimihiko Okazaki*

Received: May 26, 2018;   Published: June 08, 2018

DOI: 10.32474/OAJOM.2018.01.000124

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

In 1969, Mutsuyuki Kochi [1,2] developed 4-Hydroxybenzaldehyde for use as a novel anti-tumor agent without side effect and acquired its patent. Accordingly, this medicine is capable of preventing carcinogenesis when used in sufficient quantity. To treat advanced cancers, an oncologist should start with giving the cancer patient a small dose of the 4-Hydroxybenzaldehyde to avoid the possible severe hemorrhage of a tumor caused by excessive necrosis. Therefore, it has useful applications in treating lymphomas and leukemia’s. Consequently, those who have these diseases can receive a considerably large dose of the medicine. The mechanism of action of the medicine is apparently competitive inhibition of tyrosine kinase, which is the rate-limiting enzyme in the pathway of carcinogenesis [3,4].

Abstract| Case Report| References|